1179
PERSISTENCE, EFFICACY AND TOLERANCE OF SUBCUTANEOUS INFLIXIMAB AFTER SWITCH FROM INTRAVENOUS INFLIXIMAB IN IBD PATIENTS IN REMISSION:: ONE-TEAR RESULTS FROM A MULTICENTER PROSPECTIVE COHORT
Date
May 21, 2024
Tracks
Related Products
ENDOSCOPIC SUBMUCOSAL DISSECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS FOR VISIBLE DYSPLASIA: A FRENCH RETROSPECTIVE MULTICENTRIC STUDY
BACKGROUND: Biological treatment in inflammatory bowel disease (IBD) patients is currently hampered by high non-response rates. To enhance personalized medicine and predict response to biological therapeutics such as vedolizumab, the working mechanism should be elucidated…
REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT: RESULTS FROM THE TORUS STUDY
BACKGROUND: Prevention of postoperative recurrence (POR) in Crohn’s disease (CD) after ileo-colonic (IC) resection is still a highly debated topic. Prophylactic immunosuppression after surgery is currently recommended in presence of at least one clinical risk factor (RF)…
VEDOLIZUMAB PREVENTS POSTOPERATIVE REUCURRENCE IN CROHN’S DISEASE: RESULTS OF THE REPREVIO TRIAL
This session presents the best submitted clinical abstracts as determined by their specific council sections…
EFFICACY OF MIRIKIZUMAB IN COMPARISON TO USTEKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 VIVID 1 STUDY
BACKGROUND: The primary objective of the VIVID-1 trial (NCT03926130) was to demonstrate efficacy and safety of mirikizumab (miri), a p19-directed anti-IL-23 antibody, compared to placebo (PBO) in patients (pts) with moderate-to-severe Crohn’s disease…